SG11202102492PA - Combination therapy for the treatment of prostate cancer - Google Patents

Combination therapy for the treatment of prostate cancer

Info

Publication number
SG11202102492PA
SG11202102492PA SG11202102492PA SG11202102492PA SG11202102492PA SG 11202102492P A SG11202102492P A SG 11202102492PA SG 11202102492P A SG11202102492P A SG 11202102492PA SG 11202102492P A SG11202102492P A SG 11202102492PA SG 11202102492P A SG11202102492P A SG 11202102492PA
Authority
SG
Singapore
Prior art keywords
treatment
prostate cancer
combination therapy
therapy
combination
Prior art date
Application number
SG11202102492PA
Other languages
English (en)
Inventor
Sarah Christine Attwell
Eric Campeau
Sanjay Lakhotia
Original Assignee
Zenith Epigenetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenith Epigenetics Ltd filed Critical Zenith Epigenetics Ltd
Publication of SG11202102492PA publication Critical patent/SG11202102492PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41661,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
SG11202102492PA 2018-09-13 2019-09-13 Combination therapy for the treatment of prostate cancer SG11202102492PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862730869P 2018-09-13 2018-09-13
US201862737612P 2018-09-27 2018-09-27
US201862778185P 2018-12-11 2018-12-11
PCT/US2019/050970 WO2020056232A1 (en) 2018-09-13 2019-09-13 Combination therapy for the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
SG11202102492PA true SG11202102492PA (en) 2021-04-29

Family

ID=69778254

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102492PA SG11202102492PA (en) 2018-09-13 2019-09-13 Combination therapy for the treatment of prostate cancer

Country Status (12)

Country Link
US (1) US20220117942A1 (zh)
EP (1) EP3849544A4 (zh)
JP (1) JP7441214B2 (zh)
KR (1) KR20210060515A (zh)
CN (1) CN112912075B (zh)
AU (1) AU2019338483A1 (zh)
CA (1) CA3112396A1 (zh)
IL (1) IL281281A (zh)
MX (1) MX2021002884A (zh)
SG (1) SG11202102492PA (zh)
TW (1) TWI816880B (zh)
WO (1) WO2020056232A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117136057A (zh) * 2021-02-22 2023-11-28 赛尔基因昆蒂赛尔研究公司 用于治疗前列腺癌的溴结构域(bet)抑制剂
CN114644687B (zh) * 2022-04-07 2023-06-27 华中科技大学同济医学院附属协和医院 一种可拮抗rbm25蛋白rna结合活性的多肽rbip-21及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP2621483A1 (en) * 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
WO2015002754A2 (en) * 2013-06-21 2015-01-08 Zenith Epigenetics Corp. Novel bicyclic bromodomain inhibitors
CN105899223A (zh) * 2013-10-28 2016-08-24 加利福尼亚大学董事会 转移性前列腺癌的治疗
NO2719005T3 (zh) * 2014-07-28 2018-01-20
WO2016171470A1 (en) * 2015-04-21 2016-10-27 Kainos Medicine, Inc. Bromodomain-inhibiting compounds and methods to prevent or treat a cancer
WO2017216772A2 (en) * 2016-06-16 2017-12-21 The University Of Chicago Methods and compositions for treating breast and prostate cancer
US20180141939A1 (en) * 2016-11-22 2018-05-24 Gilead Sciences, Inc. Solid forms of a bet inhibitor
US20180153867A1 (en) * 2016-12-06 2018-06-07 Gilead Sciences, Inc. Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent

Also Published As

Publication number Publication date
WO2020056232A1 (en) 2020-03-19
EP3849544A4 (en) 2022-06-08
JP2022500431A (ja) 2022-01-04
US20220117942A1 (en) 2022-04-21
AU2019338483A1 (en) 2021-04-08
MX2021002884A (es) 2021-07-15
JP7441214B2 (ja) 2024-02-29
CA3112396A1 (en) 2020-03-19
CN112912075A (zh) 2021-06-04
EP3849544A1 (en) 2021-07-21
CN112912075B (zh) 2023-04-04
KR20210060515A (ko) 2021-05-26
IL281281A (en) 2021-04-29
TW202017926A (zh) 2020-05-16
TWI816880B (zh) 2023-10-01

Similar Documents

Publication Publication Date Title
IL281256A (en) Combined treatment for the treatment of triple-negative breast cancer
IL291844B1 (en) smc combined therapy for cancer treatment
IL267795A (en) Combined treatment for cancer
IL280337A (en) LAG-3 combination therapy for cancer treatment
ZA202206743B (en) Therapy for the treatment of cancer
IL281845A (en) Combined treatment for cancer
PT3609497T (pt) Niraparib, acetato de abiraterona e prednisona para o tratamento do cancro da próstata
IL284162A (en) Integrated healing for cancer treatment
IL275949A (en) Combined treatment for the treatment of cancer or its prevention
IL282093A (en) Combination therapy for cancer
IL279591A (en) Cancer treatment methods using combination therapy
IL264589A (en) Combined treatment for pancreatic cancer
IL281439A (en) Combined treatment for blood cancer
IL266993A (en) Combined therapy for cancer treatment
IL281281A (en) Combined treatment for prostate cancer
IL307465A (en) Combined therapies for cancer treatment
IL276073A (en) Combined treatment for the treatment of cancer or its prevention
IL276074A (en) Combined treatment for the treatment of cancer or its prevention
IL275981A (en) Combined therapies for the treatment of hepatocellular carcinoma
IL275860A (en) Combined treatment for the treatment of cancer or its prevention
IL263905A (en) Combined cancer treatment
SG11202100571TA (en) Anti-lypd3 car t-cell therapy for the treatment of cancer
IL253642A0 (en) Combined treatment for cancer
GB201808636D0 (en) Combination therapy for treating or preventing cancer
GB201808632D0 (en) Combination therapy for treating or preventing cancer